Christopher Thomas Giordano insider trades: Tenax Therapeutics (TENX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TENX | ↑ Buy | 10,850 | $1.85 | $20K | Direct | Sep 15, 2026 (0d) |
| Nov 20, 2025 | TENX | ↑ Buy | 2,605 | $7.68 | $20K | Direct | Nov 20, 2025 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TENX insiders
Open-market trades in the last 12 months
About Christopher Thomas Giordano's insider trades
Christopher Thomas Giordano is CEO at Tenax Therapeutics (TENX). Since Nov 20, 2025, Christopher has reported 2 open-market purchases worth $40K and no sales on SEC Form 4. In the last 12 months: 2 buys ($40K).
Their filings also include grants and awards (5 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TENX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.